Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

Simon Nadel; Brahm Goldstein; Mark D. Williams; Heidi Dalton; Mark Peters; William L. Macias; Shamel A. Abd-Allah; Howard Levy; Robinette Angle; Dazhe Wang; David P. Sundin; Brett Giroir

doi:10.1016/S0140-6736(07)60411-5

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

Simon Nadel, Brahm Goldstein, Mark D. Williams, Heidi Dalton, Mark Peters, William L. Macias, Shamel A. Abd-Allah, Howard Levy, Robinette Angle, Dazhe Wang, David P. Sundin, Brett Giroir

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	836-843
Number of pages	8
Journal	The Lancet
Volume	369
Issue number	9564
DOIs	https://doi.org/10.1016/S0140-6736(07)60411-5
State	Published - Mar 10 2007

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1016/S0140-6736(07)60411-5License: Unspecified

OpenUrl availability

Full text

Cite this

@article{cde88f07409545a8822111a1ce965043,

title = "Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial",

author = "Simon Nadel and Brahm Goldstein and Williams, {Mark D.} and Heidi Dalton and Mark Peters and Macias, {William L.} and Abd-Allah, {Shamel A.} and Howard Levy and Robinette Angle and Dazhe Wang and Sundin, {David P.} and Brett Giroir",

note = "Funding Information: This study was supported by Eli Lilly. S Nadel, B Goldstein, and B Giroir have been paid consultants for Eli Lilly. S Nadel, B Goldstein, H Dalton, M Peters, and B Giroir have participated in previous trials sponsored by Eli Lilly. M D Williams, W L Macias, H Levy, D Wang, D P Sundin, and R Angle are all employees and stockholders of Eli Lilly. S A Abd-Allah has no conflict of interest to declare. ",

year = "2007",

month = mar,

day = "10",

doi = "10.1016/S0140-6736(07)60411-5",

language = "English",

volume = "369",

pages = "836--843",

journal = "The Lancet",

issn = "0140-6736",

number = "9564",

}

TY - JOUR

T1 - Drotrecogin alfa (activated) in children with severe sepsis

T2 - a multicentre phase III randomised controlled trial

AU - Nadel, Simon

AU - Goldstein, Brahm

AU - Williams, Mark D.

AU - Dalton, Heidi

AU - Peters, Mark

AU - Macias, William L.

AU - Abd-Allah, Shamel A.

AU - Levy, Howard

AU - Angle, Robinette

AU - Wang, Dazhe

AU - Sundin, David P.

AU - Giroir, Brett

N1 - Funding Information: This study was supported by Eli Lilly. S Nadel, B Goldstein, and B Giroir have been paid consultants for Eli Lilly. S Nadel, B Goldstein, H Dalton, M Peters, and B Giroir have participated in previous trials sponsored by Eli Lilly. M D Williams, W L Macias, H Levy, D Wang, D P Sundin, and R Angle are all employees and stockholders of Eli Lilly. S A Abd-Allah has no conflict of interest to declare.

PY - 2007/3/10

Y1 - 2007/3/10

UR - http://www.scopus.com/inward/record.url?scp=33847687731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847687731&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(07)60411-5

DO - 10.1016/S0140-6736(07)60411-5

M3 - Article

C2 - 17350452

SN - 0140-6736

VL - 369

SP - 836

EP - 843

JO - The Lancet

JF - The Lancet

IS - 9564

ER -

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this